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Abstract  
 
 Homocystinuria is an inborn error of amino acid metabolism caused by 
deficiency of cystathionine ß-synthase (CBS) activity, leading to the accumulation of 
homocysteine (Hcy) and methionine (Met) in biological fluids and high urinary 
excretion of homocystine (Hci). This accumulation leads to a variety of clinical 
manifestations, in different organs and tissues, as thinning and lengthening of the long 
bones, osteoporosis, dislocation of the ocular lens, thromboembolism and mental 
retardation, but the pathophysiology of this disease is not completely understood. In this 
context, this review addresses some findings obtained from patients and animal studies 
indicating that oxidative stress plays an important role in the pathophysiology of 
homocystinuria. Several studies have shown that enzymatic and non-enzymatic 
antioxidant defenses are decreased, as well as markers of lipid, protein, and DNA 
oxidative damage have been reported increased in blood, brain, liver and muscle in the 
animal models studied, as well as in homocystinuric patients, which may be due to an 
increased free radical generation or secondary to the deprivation of micronutrients 
which are essential for these defenses. A considerable set of data from in vitro and in 
vivo animal studies have shown that Hcy induces reactive species formation in brain 
rodent. Considering these findings, it is well established that oxidative stress may 
contribute to the damage found in homocystinuric patients. This review offers new 
perspectives for the treatment in homocystinuria, which may include the use of 
appropriate antioxidants as a novel adjuvant therapy for the patients. 
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1. Introduction  
 
 Homocystinuria is an autosomal recessive disorder of amino acid metabolism 
caused in most cases by deficiency of cystathionine ß-synthase (CBS), the enzyme that 
catalyzes the transsulfuration of homocysteine (Hcy) to cystathionine. CBS is a 
pyridoxine (vitamin B6) dependent enzyme. Untreated patients have accumulation of 
Hcy and methionine (Met) in biological fluids and high urinary excretion of 
homocystine (Hci). Not only deficient activity of CBS, but  other genetic defects may 
lead to increased of Hcy in the plasma, such as mutations that inactivate the enzymes 
methionine synthase and methylenetetrahydrofolate reductase (MTHFR) [1]. Mudd et al 
[1] found estimates of the frequency of homocystinuria ranging from 1 in 58,000 to 1 in 
1,000,000 in countries that systematically screen newborns.   
In CBS deficiency, there is a variety of clinical manifestations in different 
organs and tissues, as thinning and lengthening of the long bones, osteoporosis, 
dislocation of the ocular lens, thromboembolism and mental retardation [1]. There are 
two different clinical forms of CBS deficiency: pyridoxine-responsive and pyridoxine-
non-responsive [2]. Treatment for B6-responsive patients consists in the use the 
cofactor of CBS, vitamin B6, at a dose of approximately 200 mg/day, and also protein-
restricted diet. B6-non-responsive patients require restriction of Met intake and cystine 
supplementation [3]. An alternate therapy can be the use of betaine, 6 to 9 g/day [4]. 
Moreover, folate and vitamin B12 are also used, 5 mg/day for folic acid and 1 mg 
intramuscular per month for vitamin B12 in the form of hydroxocobalamin [3].  
 Mudd et al [2] considered that is more likely that the pathogenesis of 
homocystinuria is related to the Hcy excess or cysteine deficiency than to the 
accumulation of Met. Although the pathogenesis of this disease is not completely 
understood, it has been suggested that oxidative stress plays an important role in the 
pathophysiology in this disorder [5-11]. Besides, studies done in animal models have 
demonstrated an association between Hcy and oxidative stress [12-17].  
 Oxidative stress is defined as an imbalance between the production of reactive 
species and the decrease in the antioxidant defenses, in favor of the former, leading to 
cell damage. Increasing evidence has shown that damage caused by free radicals and 
reactive species are an important contributing factor in chronic-inflammatory, vascular, 
neoplasic and neurodegenerative diseases [18]. Regarding to important role of oxidative 
stress in neurodegenerative diseases, various findings have shown that oxidative stress 
participates in the pathophysiology of some inborn errors of metabolism (IEM) such as 
aminoacidopathies and organic acidemia [7,19]. Although the relation between 
oxidative stress and IEM pathophysiology is not well elucidated, the accumulation of 
toxic metabolites is appointed as the main reason for the increase of free radicals [19]. 
 Therefore, in the present work we aim to review the parameters of oxidative 
stress in homocystinuric patients by CBS deficiency and the contribution from animal 
models studies for the understanding of oxidative damage in this disease. 
 
 
2. Oxidative stress in homocystinuric patients 
 
 Oxidative damage to proteins, lipids and DNA, as well as antioxidant defenses 
and inflammatory profile have been investigated in homocystinuric patients (Table 1). It 
was verified by Vanzin and coworkers [9,10] that carbonyl content is increased in 
plasma of homocystinuric patients at diagnosis and partially reduced under treatment 
when compared with healthy individuals, indicating that there is protein oxidative 
damage and that treatment partially protect against protein oxidation. Patient’s treatment 
was based on protein restriction with supplementation of pyridoxine, folate, betaine and 
vitamin B12. It was determined by these authors the lipid peroxidation index on the 
basis of malondialdehyde (MDA) levels and it was observed that plasma MDA levels in 
patients at diagnosis were significantly higher when compared to patients under 
treatment and healthy individuals, implying that patients treated presented a significant 
decrease in MDA levels when compared with patients at diagnosis. The data indicated 
that treatment prevented the lipid damage found in homocystinuric patients at diagnosis, 
but did not reach the levels found in healthy individuals [9]. Furthermore, sulfhydryl 
content was significantly lower in homocystinuric patients at diagnosis and in patients 
under treatment when compared to healthy individuals [9,10]. The total antioxidant 
status (TAS), reflecting the quantity of tissues antioxidants, was significantly lower in 
patients at diagnosis and during dietary treatment when compared to healthy people, 
suggesting that treatment was not able to prevent the decrease in the antioxidant 
defenses found at diagnosis [9]. In the same study, it was examined plasma Hcy and 
Met levels: treated patients presented a significant decrease of both amino acids (Hcy: 
140.3 ± 99.3 μmol/L; Met: 2.0 ± 0.6 μmol/L) when compared with patients at diagnosis 
(Hcy: 266.5 ± 66.7 μmol/L; Met: 2.6 ± 0.3 μmol/L), but still remained above the normal 
range (reference values: Hcy: 5 - 15 μmol/L; Met: 7 - 47 μmol/L). In order to 
investigate whether Hcy and Met levels were associated to oxidative stress, the 
parameters investigated were correlated with these two amino acids levels and it was 
verified a significant negative correlation between sulfhydryl group content and Hcy 
levels and a significant positive correlation between MDA levels and Hcy levels, 
suggesting a potential mechanistic role for Hcy in the oxidative damage. Regarding to 
Met, no correlation was found between this amino acid and the oxidative stress 
parameters, which reinforces the assumption that Met and its derivatives make little 
contribution to the oxidative manage of CBS deficiency [9,10]. 
 The lipid [total cholesterol, HDL cholesterol, LDL cholesterol, oxidized LDL 
cholesterol, apolipoprotein A1 (ApoA-1)] and inflammatory [Interleukin-6 (IL-6), 
Interleukin-1β (IL-1β), Interferon-γ (IFN-γ)] profiles and the activities of enzymes 
paraoxonase (PON1) and butyrylcholinesterase (BuChE) in plasma of CBS-deficient 
patients at diagnosis and under treatment were also evaluated by Vanzin et al [10]. All 
those parameters measured were correlated with the Hcy, folic acid, and vitamin B12 
concentrations. With regard to lipid profile, it was found a significant decrease in HDL 
and ApoA-1 levels in treated or not homocystinuric patients at diagnosis when 
compared to healthy individuals. LDL and oxidized LDL levels were statistically 
similar between patients and healthy individuals. Total cholesterol levels were 
significantly reduced in the CBS-deficient patients, probably due to the decrease in 
HDL levels. PON1 activity was decreased in homocystinuric patients at diagnosis and 
under treatment when compared with healthy people, differently from BuChE activity 
that was increased only in the untreated patients when compared the healthy individuals 
and patients under treatment. It was verified a significant positive correlations between 
PON1 activity and sulfhydryl groups content and between HDL and ApoA-1 levels. 
Besides, it was demonstrated that IL-6 was significantly higher in patients at diagnosis 
and there was a tendency to reduction in the IL-6 levels in patients under treatment 
when compared the healthy individuals. It was found a significant positive correlation 
between IL-6 levels and carbonyl groups content, indicating a possible association 
between inflammation and oxidative protein damage. Moreover, it was also evaluated 
the IL-1β and INF-γ levels which were statistically similar between CBS-deficient 
patients and healthy individuals. It was found a significant positive correlation between 
vitamin B12 and ApoA-1 levels, as well as a significant positive correlation between 
vitamin B12 levels and PON1. These findings suggest that vitamin B12 could be 
essential to increase the ApoA-1 levels and PON1 activity in CBS-deficient patients, 
which is interesting since these components demonstrate important atheroprotective 
effects [20-22] that could, at least in part, decrease or revert the vascular alterations 
found in these patients. The vitamin B12 levels were similar in treated or not treated 
CBS-deficient patients, indicating a poor adherence to the treatment. Additionally, it 
was demonstrated a significant negative correlation between folic acid and total Hcy 
concentrations. Folic acid was increased in treated patients when compared with not 
treated patients [10]. 
 Pullin and coworkers [23] verified what the vitamin C ameliorates endothelial 
dysfunction in patients with homocystinuria, independent of changes in Hcy 
concentration. They also concluded that vitamin C should therefore be considered as an 
additional adjunct to therapy to reduce the potential long-term risk of atherothrombotic 
disease. 
 F2-isoprostanes represent a family of bioactive prostaglandin F2–like 
compounds that are produced from arachidonic acid through a non-enzymatic process of 
lipid peroxidation. Among F2-isoprostanes, of particular interest is 8-isoprostaglandin 
F2α, which induces vasoconstriction and modulates the function of human platelets and 
can be increased in association with several cardiovascular risk factors. Davi and 
coworkers [24] verified a significant positive correlation between plasma Hcy levels 
and urinary 8-isoprostaglandin F2α in CBS-deficient patients. Urinary 8-
isoprostaglandin F2α and 11-dehydrothromboxane B2 excretion was significantly 
higher in CBS-deficient patients when compared to healthy individuals and it was 
verified a significant positive correlation between these biomarkers. The vitamin E 
supplementation was associated with statistically significant reductions in urinary 8-
isoprostaglandin F2α and 11-dehydrothromboxane B2 levels, but 2 weeks of vitamin E 
supplementation at 600 mg/day induced a reduction but failed to normalize enhanced 
lipid peroxidation. These preliminary observations suggest a potential role for 
antioxidant therapy in attenuating Hcy dependent oxidative changes that may promote 
atherothrombosis in this disease. 
 Another study of Vanzin and coworkers [11] showed that Hcy induces DNA 
damage in vivo and in vitro in a dose-dependent manner in white blood cells. It was 
verified that DNA damage was significantly higher in the CBS-deficient patients under 
treatment when compared the healthy individuals, suggesting that DNA damage in these 
patients can be correlated with the high plasma Hcy levels found, since the Hcy average 
level of treated patients included in this study was 166.5 ± 117.1 μmol/L (average ± 
standard deviation), remaining above of ideal levels. 
 An important component of the endogenous antioxidant defense opposing the 
deleterious vascular effects of free radicals is superoxide dismutase (SOD), present in 
the vascular wall. Among the existing SOD isoenzymes, more of 90% of interstitial 
SOD is extracellular superoxide dismutase (EC-SOD). It was demonstrated a significant 
positive correlation between EC-SOD and total Hcy in CBS-deficient patients, what 
could represent a protective antioxidant response to Hcy-induced oxidative damage and 
could contribute to reducing cardiovascular risk in homocystinuric patients. In contrast 
there were no correlations between EC-SOD and the Met concentrations [6].             
 Vilaseca-Buscà and coworkers [7] evaluated the antioxidant status in patients 
affected by inborn errors of metabolism (including CBS-deficient patients) through the 
measurement of erythrocyte antioxidant enzyme activities, as SOD. The SOD activity 
was significantly higher in the patients with protein-free diet when compared with the 
patients on protein restricted diet or with healthy individuals, suggesting an induction of 
enzyme protein synthesis owing to an excess of free radical generation. The lower 
activities observed in patients on protein restriction may likely be due to a deficient 
bioavailability of antioxidant cofactors. 
  
 
3. Oxidative stress in animal models of homocystinuria 
 
 Animal models are useful to better understand the pathophysiology of human 
diseases. In the study of Matté and coworkers [25] it was investigated the effect of 
chronic hyperhomocysteinemia (Hhcy) on some parameters of oxidative damage, 
catalase (CAT), SOD, glutathione peroxidase (GPx),  total radical-trapping antioxidant 
potential (TRAP) and DNA damage in blood and parietal cortex of rats. In order to 
evaluate whether DNA damage was permanent after cell division, it was also 
investigated the effect of Hcy on the micronucleus test, and it was showed that Hhcy did 
not alter micronucleus frequency in blood of rats. It was also evaluated the effect of 
folic acid on biochemical alterations elicited by Hhcy. The results demonstrated that 
chronic Hcy administration increased DNA damage, evaluated by comet assay, and 
significantly reduced in TRAP, CAT and GPx activities in parietal cortex. SOD and 
CAT activities were increased, TRAP was decreased and GPx activity was not altered in 
blood of rats. It was also verified that folic acid concurrent administration per se did not 
alter the activities of CAT, SOD, GPx, TRAP and DNA damage but prevented the 
inhibition of these parameters caused by Hcy. The results allowed to propose that the 
supplementation with folic acid can be used as an adjuvant therapy in disorders that 
accumulate Hcy, possibly by its antioxidant and DNA stability maintenance properties. 
 Moreover, it was investigated the effect of chronic administration of Hcy on 
antioxidant enzymes CAT and SOD, on glutamate uptake and in the Na(+),K(+)-
ATPase activity in hippocampus of rats. The results showed a significant reduction in 
these parameters. Besides, vitamin C alone did not alter these parameters, but when 
administered concomitantly with Hcy, it was able to prevent the inhibition caused by 
Hcy. It was also evaluated the levels of 2'7'dichlorofluorescein (DCF) that was 
increased in the hippocampus. Vitamin C, when administered concomitantly with Hcy, 
was able to prevent the damage caused by the amino acid [15]. 
 Furthermore, it was evaluated the effect of acute Hcy administration in some 
parameters of oxidative stress, TRAP, CAT, SOD and GPx and on Na(+),K(+)-ATPase 
activity and the effect of chronic pretreatment with vitamins E and C in rat 
hippocampus. Results showed that Hcy significantly decreased TRAP, Na(+),K(+)-
ATPase and CAT activities, without affecting the activities of SOD and GPx. The 
chronic pretreatment with vitamins E and C per se did not alter these parameters, but 
prevented the reduction of TRAP, Na(+),K(+)-ATPase and CAT activities caused by 
Hcy [12]. 
 The effect of the acute administration of Hcy on memory in rats and the action 
of vitamins E and C on the effects produced by Hcy was investigated by Reis et al [26]. 
The memory was significantly impaired in Hcy-treated group, an effect probably 
mediated by oxidative stress, whereas the rats chronically treated with vitamins E and C 
had this effect prevented. 
 The in vitro effect of Hcy on some parameters of oxidative stress in the rat 
hippocampus were investigated by Streck et al [13]. The Hcy significantly increased 
thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation, and 
decreased TRAP, but did not change in vitro the antioxidant enzymes SOD, CAT, and 
GPx in rat hippocampus. 
 Matté and coworkers [27] investigated the chronic Hcy administration on 
hepatic antioxidant status, TRAP and total antioxidant reactivity (TAR), suggesting a 
reduction on quantity and quality of non-enzymatic antioxidants in liver of rats. Lipid 
peroxidation was assessed by chemiluminescence and by TBARS and both were 
increased. Also, it was verified a reduction on total thiol content, such as sulfhydryl 
groups and antioxidant glutathione and a significant inhibition of hepatic CAT activity 
in rats. Histological analysis indicated the presence of inflammatory infiltrate, fibrosis 
and reduced content of glycogen/glycoprotein in liver tissue sections. The chronic Hcy 
administration did not altered alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) activities in liver and in plasma of rats. The data showed a 
consistent profile of liver injury elicited by Hcy, which could contribute to explain, at 
least in part, the mechanisms involved in human liver diseases associated to Hhcy.  
 In another study, the histologic evaluation of liver CBS-deficient mice showed 
development inflammation, fibrosis and hepatic steatosis concomitant with an enhanced 
expression of tissue inhibitor of metalloproteinase-1, α-smooth muscle actin, pro(α)1 
collagen type I, transforming growth factor-β1, and proinflammatory cytokines. The 
formation of carbonyl groups and the levels of MDA and 4-hydroxyalkenal (4-HNE) 
were increased in liver of mice, demonstrating an enhanced protein oxidation and lipid 
peroxidation. Moreover, the absence of caspase-3 activation, DNA fragmentation, and 
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick 
end-labeling (TUNEL)-positive cells showed that protective signals may counteract 
apoptotic signals in liver of CBS-deficient mice [14]. 
 The study of Kolling et al [17] investigated the effect of chronic Hhcy on some 
parameters of oxidative stress and the effect of creatine on biochemical alterations, but 
this time in skeletal muscle of rats. It was showed that chronic Hcy administration 
increased the DCF oxidation, an index of production of reactive species, and the 
TBARS levels, an index of lipid peroxidation. Antioxidant enzyme activities, SOD and 
CAT were also increased, but GPx activity was not altered. The content of glutathione 
(GSH), sulfhydryl and carbonyl were decreased, as well as nitrite levels. Moreover, the 
creatine concurrent administration prevented some Hcy effects probably by its 
antioxidant properties. Based on these findings, it was suggested that creatine may be 
used as adjunctive therapy for ameliorating the symptoms associated with oxidative 
insult that can be found in homocystinuric patients. 
 The effect of chronic Hhcy on some parameters of oxidative stress in the rat lung 
was evaluated by Cunha and coworkers [16]. The chronic Hhcy significantly increased 
TBARS and protein carbonyl content, suggesting that this amino acid causes lipid 
peroxidation and oxidative damage to protein. Also, the Hcy significantly increased the 
levels of reactive species in lung indicated by DCF fluorescence assay. Next, it was 
evaluated the enzymatic antioxidant defenses SOD, CAT and GPx, and it was observed 
that Hcy significantly increases SOD activity and reduced the CAT and GPx activities. 
Moreover, it was showed that chronic Hcy administration induced a decrease in the 
TRAP, suggesting that this amino acid cause a reduction in non-enzymatic antioxidants. 
It was also observed that Hcy significantly reduced the GSH content and glucose 6-
phosphate dehydrogenase (G6PD) activity and not changed the nitrite levels. These 
findings showed a consistent profile of oxidative stress in the lung of rats elicited by 
Hcy. 
 Acetylcholine is a neurotransmitter hydrolyzed by two different types of 
cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). 
BuChE is present in all tissues, including serum, heart, vascular endothelia and nervous 
system [28]. Schulpis and coworkers [29] determined the in vitro effects of Hcy, Hci 
and Met and the mixture of these three amino acids simulating CBS-deficiency on 
AChE activity in hippocampus of rats. The preincubation with the amino acids Hcy or 
Met resulted in a significant activation of AChE, whereas the Hci inhibited the enzyme 
activity. The presence of SH-group in both the amino acids, Hcy and Met, could explain 
AChE activation. Furthermore, the in vitro CBS-deficiency resulted in a high activation 
AChE activity, since each one of the SH-group containing amino acids produced 
simultaneously significant enzyme stimulation. 
  In this context, in the study of Stefanello and coworkers [30] it was investigated 
the acute and chronic effect of Hcy administration on BuChE activity in serum of rats. 
The results showed that acute and chronic administration of Hcy significantly decreased 
BuChE activity. Furthermore, the rats were pretreated for one week with vitamins E and 
C. Per se, the vitamins not alter BuChE activity, but prevented the reduction of this 
enzyme activity caused by acute administration of Hcy, suggesting that the inhibitory 
effect of Hcy on BuChE activity is probably mediated by free radicals. Another study of 
Stefanello et al [31] investigated the in vitro effects of Hcy on platelet Na(+),K(+)-
ATPase and serum BuChE activities of young rats. Results showed that Na(+),K(+)-
ATPase and BuChE activities were significantly inhibited by Hcy. The inhibition of 
Na(+),K(+)-ATPase and BuChE activities might be one useful peripheral marker for the 
neurotoxic effects of Hcy.  
 Na(+),K(+)-ATPase is a fundamental enzyme responsible for maintaining the 
ionic gradient necessary for neuronal excitability and it is present at high concentrations 
in the brain cellular membrane [32] and it is known that the activity of this enzyme is 
decreased in various neurodegenerative disorders [33]. Streck and coworkers [34] 
studied the chronic Hcy administration in brain of young rats and Na(+),K(+)-ATPase 
and Mg(2+)-ATPase activities were determined in the hippocampus of treated Hcy rats. 
Chronic administration of Hcy significantly decreased Na(+),K(+)-ATPase activity but 
did not alter Mg(2+)-ATPase activity. In another study, Streck and coworkers [35] 
investigated the effects of preincubation of hippocampus homogenates in the presence 
of Hcy or Met on Na(+),K(+)-ATPase and Mg(2+)-ATPase activities in synaptic 
membranes of rats. Hcy significantly inhibited Na(+),K(+)-ATPase activity, whereas 
Met had no effect. Mg(2+)-ATPase activity was not altered by the metabolites. It was 
also evaluated the effect of incubating trolox (vitamin E analogue) alone or with Hcy on 
Na(+),K(+)-ATPase and Mg(2+)-ATPase activities in synaptic membranes from the 
hippocampus of rats. Trolox prevented the inhibitory effect of Hcy on Na(+),K(+)-
ATPase activity. Besides, Streck et al [36] determined the in vitro effects of Hcy and 
Met on Na(+),K(+)-ATPase, and Mg(2+)-ATPase activities in synaptic membranes 
from the hippocampus of rats. The results showed that both metabolites significantly 
inhibit Na(+),K(+)-ATPase but not Mg(2+)-ATPase activity at concentrations usually 
observed in plasma of homocystinuric patients. Furthermore, incubation of hippocampal 
homogenates with Hcy also elicited an inhibition of the enzyme activity which was 
however prevented by the simultaneous addition of cysteine to the medium. In addition, 
cysteine or Met per se did not modify the two enzymatic activities. These findings 
indicate that oxidation of critical groups in the enzyme may possibly be involved in Hcy 
inhibitory effect. Considering that Na(+),K(+)-ATPase plays a crucial role in the central 
nervous system, these results suggest that the inhibition of this enzyme activity by Hcy 
is possible mediated by free radicals and may contribute to the neurological dysfunction 
found in homocystinuric patients. 
 Table 2 describes the oxidative stress parameters studied in tissues and 
biological fluids from animal models of homocystinuria. These findings showed a 
consistent profile of oxidative stress in the brain, blood, liver, muscle and lung of rats 
elicited by Hcy, which could explain, at least in part, the mechanisms involved in 
disease that is present in some homocystinuric patients. 
  
 
4. Concluding remarks 
 
 Homocystinuric patients at diagnosis and during dietary therapy are susceptible 
to oxidative damage caused by an increase in free radical production and by a depletion 
in antioxidant capacity, with an increase of biomarkers reflecting lipid, protein, and 
DNA damage, probably secondary to increased formation of reactive species or 
secondary to the deprivation of micronutrients which are essential for these defenses. 
Also, mounting evidence obtained from experimental animal homocystinuric models 
indicated that oxidative stress may occur in the blood, brain, liver, lung and muscle of 
rats induced by Hcy. The data from literature, obtained from humans and experimental 
animal homocystinuric models, suggest that oxidative stress may be involved in the 
pathophysiology of the cardiovascular and neurological damage characteristic in this 
disease and, therefore, the administration of compounds with antioxidant properties 
could be considered as an adjuvant tool for being used in association with the present 
mainstay therapy when treating homocystinuric patients. Therefore, clinical studies 
should evaluate the use of antioxidants in further researches. 
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 Tables 
Table 1 Oxidative stress and inflammatory parameters evaluated in biological fluids 
from homocystinuric patients at diagnosis and during dietary treatment. 
Parameter Diagnosis Treatment Reference 
 
Lipid peroxidation 
     MDA levels 
     8-isoprostaglandin F2α 
    11-dehydrothromboxane 
 
Protein oxidation 
    Carbonyl content 
    Sulfhydryl content 
 
DNA damage 
 
Antioxidant defense 
    TAS levels 
    Vitamin B12 
    Vitamin E 
    Folic acid 
    SOD 
    EC-SOD 
    
Inflammatory profile 
    IL-6 
    IFN-y  
    IL-1β 
 
 
Increased* 
NM 
NM 
 
 
Increased* 
Decreased* 
 
NM 
 
 
Decreased* 
Decreased* 
NM 
Decreased* 
NM 
Increased 
 
 
Increased* 
Similar* 
Similar* 
 
 
 
Increased 
Increased 
Increased 
 
 
Increased 
Decreased 
 
Increased 
 
 
Decreased 
Decreased 
Increased 
Increased 
Increased 
Increased 
 
 
Increased 
Similar 
Similar 
 
 
 
[9] 
[24] 
[24] 
 
 
[9,10] 
[9,10] 
 
[11] 
 
 
[9] 
[10] 
[24] 
 [10] 
[7] 
[6] 
 
 
[10] 
[10] 
[10] 
 
NM: not measured 
*at late diagnosis 
 
 
 
 
 
 
 
 
 
 Table 2 Oxidative stress parameters evaluated in tissues and biological fluids from 
animal models of homocystinuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter In vitro / acute / chronic Reference 
 
Lipid peroxidation 
 
Protein oxidation 
 
DNA damage 
 
Antioxidant defense 
 
Antioxidant enzyme 
 
Activity of enzyme 
     AChE 
    BuChE  
    Na(+),K(+)-ATPase 
 
Increased 
 
Increased 
 
Increased 
 
Decreased 
 
Altered 
 
 
Increased 
Decreased 
Decreased 
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[14,16] 
 
[25] 
 
[12,13,16,25,27] 
 
[12,13,15-17,25,27] 
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